Reviewer’s report

Title: Transcutaneous Neuromodulation improved inflammation and sympathovagal ratio in Patients with Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid - A Pilot Study

Version: 2 Date: 22 May 2020

Reviewer's report:

BCAM-D-19-01778_R2_reviewer 2 comments on revision 2, 22-5-20

For future changes, in your answer, please indicate the page and line number where the change is located.

The authors have successfully addressed most questions except the following:

1. The figure legends still need more clarity. I have shown figure 3 legend as an example. Note that there are questions from me that need you to insert the answer. Don't just copy the legend.
   Figure 3. Modulation of Plasma Bile Acid (BA) Metabolism. Each row is a bile acid. Each column represents a participant.
   a) Comparison of plasma BAs in the PBC (pretreatment) group to the control group. After statistical analysis, TCDCA, TUDCA, UDCA, GCA, GDCA, GCDCA and TCA were significantly higher in the PBC patients (pretreatment) than the controls (shown by an asterix, P). Are the methods appropriate and well described?

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. 
If your reply is yes to any, please give details below.

I declare that I have no competing interests

**Reviewer Publication Consent.** I agree for my report to be made available under an Open Access Creative Commons CC-BY License ([http://creativecommons.org/licenses/by/4.0](http://creativecommons.org/licenses/by/4.0)) if this manuscript is accepted for publication. Any comments that I do not wish to be included in the published report have been included as confidential comments to the editor, which will not be published. If you are not happy for us to publish this report, please contact the editorial office before completing the review. If you wish, you can include your name in your published report. Please note you must decide whether to include your name at the start of the process and confirm this decision whenever prompted. If you change your decision later, we will not be able to publish your name.

I agree to the terms of the CC-BY 4.0 license; please **do not** publish my name with my report. (default)